Optimizing treatment switch for virologic failure during first-line antiretroviral therapy in resource-limited settings

Adedotun A. Adetunji, Chad Achenbach, Joseph Feinglass, Kristin M. Darin, Kimberly K. Scarsi, Ernest Ekong, Babafemi O. Taiwo, Isaac F. Adewole, Robert Murphy

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

We evaluated adult Nigerian patients with antiretroviral switch to second-line treatment with ritonavir-boosted protease inhibitor (PI/r)-based regimens due to virologic failure (confirmed HIV-1 RNA viral load [VL] >1000 copies/mL) during first-line antiretroviral therapy. Proportion of patients with VL >400 copies/mL and characteristics associated with nonsuppression during second-line treatment are described. Approximately 15% of patients (34 of 225) had VL >400 copies/mL at 1-year after treatment switch to PI/r-based regimens. In adjusted analyses, VL ≥5 log10 copies/mL at treatment switch (odds ratio [OR] 2.90 [confidence interval (CI) 1.21-6.93]); duration of first-line treatment after virologic failure >180 days (OR 2.56 [CI 1.0-6.54]); and PI/r regimen adherence <90% (OR 3.27 [CI 1.39-7.68]) were associated with VL >400 copies/mL at 1 year of second-line treatment. We therefore recommend that the maximum permissible time between suspicion of virologic failure and completion of antiretroviral treatment switch should not exceed 6 months when patients develop first-line antiretroviral failure in resource-limited settings.

Original languageEnglish (US)
Pages (from-to)236-240
Number of pages5
JournalJournal of the International Association of Providers of AIDS Care
Volume12
Issue number4
DOIs
StatePublished - Jul 1 2013

Fingerprint

Viral Load
Protease Inhibitors
Therapeutics
Odds Ratio
Confidence Intervals
Ritonavir
HIV-1
RNA

Keywords

  • ART
  • antiretroviral
  • first-line
  • treatment switch
  • virologic failure

ASJC Scopus subject areas

  • Immunology
  • Dermatology
  • Infectious Diseases

Cite this

Optimizing treatment switch for virologic failure during first-line antiretroviral therapy in resource-limited settings. / Adetunji, Adedotun A.; Achenbach, Chad; Feinglass, Joseph; Darin, Kristin M.; Scarsi, Kimberly K.; Ekong, Ernest; Taiwo, Babafemi O.; Adewole, Isaac F.; Murphy, Robert.

In: Journal of the International Association of Providers of AIDS Care, Vol. 12, No. 4, 01.07.2013, p. 236-240.

Research output: Contribution to journalArticle

Adetunji, Adedotun A. ; Achenbach, Chad ; Feinglass, Joseph ; Darin, Kristin M. ; Scarsi, Kimberly K. ; Ekong, Ernest ; Taiwo, Babafemi O. ; Adewole, Isaac F. ; Murphy, Robert. / Optimizing treatment switch for virologic failure during first-line antiretroviral therapy in resource-limited settings. In: Journal of the International Association of Providers of AIDS Care. 2013 ; Vol. 12, No. 4. pp. 236-240.
@article{64522efc845442e6893dfa456280b7cb,
title = "Optimizing treatment switch for virologic failure during first-line antiretroviral therapy in resource-limited settings",
abstract = "We evaluated adult Nigerian patients with antiretroviral switch to second-line treatment with ritonavir-boosted protease inhibitor (PI/r)-based regimens due to virologic failure (confirmed HIV-1 RNA viral load [VL] >1000 copies/mL) during first-line antiretroviral therapy. Proportion of patients with VL >400 copies/mL and characteristics associated with nonsuppression during second-line treatment are described. Approximately 15{\%} of patients (34 of 225) had VL >400 copies/mL at 1-year after treatment switch to PI/r-based regimens. In adjusted analyses, VL ≥5 log10 copies/mL at treatment switch (odds ratio [OR] 2.90 [confidence interval (CI) 1.21-6.93]); duration of first-line treatment after virologic failure >180 days (OR 2.56 [CI 1.0-6.54]); and PI/r regimen adherence <90{\%} (OR 3.27 [CI 1.39-7.68]) were associated with VL >400 copies/mL at 1 year of second-line treatment. We therefore recommend that the maximum permissible time between suspicion of virologic failure and completion of antiretroviral treatment switch should not exceed 6 months when patients develop first-line antiretroviral failure in resource-limited settings.",
keywords = "ART, antiretroviral, first-line, treatment switch, virologic failure",
author = "Adetunji, {Adedotun A.} and Chad Achenbach and Joseph Feinglass and Darin, {Kristin M.} and Scarsi, {Kimberly K.} and Ernest Ekong and Taiwo, {Babafemi O.} and Adewole, {Isaac F.} and Robert Murphy",
year = "2013",
month = "7",
day = "1",
doi = "10.1177/1545109712463733",
language = "English (US)",
volume = "12",
pages = "236--240",
journal = "Journal of the International Association of Providers of AIDS Care",
issn = "2325-9574",
publisher = "SAGE Publications Inc.",
number = "4",

}

TY - JOUR

T1 - Optimizing treatment switch for virologic failure during first-line antiretroviral therapy in resource-limited settings

AU - Adetunji, Adedotun A.

AU - Achenbach, Chad

AU - Feinglass, Joseph

AU - Darin, Kristin M.

AU - Scarsi, Kimberly K.

AU - Ekong, Ernest

AU - Taiwo, Babafemi O.

AU - Adewole, Isaac F.

AU - Murphy, Robert

PY - 2013/7/1

Y1 - 2013/7/1

N2 - We evaluated adult Nigerian patients with antiretroviral switch to second-line treatment with ritonavir-boosted protease inhibitor (PI/r)-based regimens due to virologic failure (confirmed HIV-1 RNA viral load [VL] >1000 copies/mL) during first-line antiretroviral therapy. Proportion of patients with VL >400 copies/mL and characteristics associated with nonsuppression during second-line treatment are described. Approximately 15% of patients (34 of 225) had VL >400 copies/mL at 1-year after treatment switch to PI/r-based regimens. In adjusted analyses, VL ≥5 log10 copies/mL at treatment switch (odds ratio [OR] 2.90 [confidence interval (CI) 1.21-6.93]); duration of first-line treatment after virologic failure >180 days (OR 2.56 [CI 1.0-6.54]); and PI/r regimen adherence <90% (OR 3.27 [CI 1.39-7.68]) were associated with VL >400 copies/mL at 1 year of second-line treatment. We therefore recommend that the maximum permissible time between suspicion of virologic failure and completion of antiretroviral treatment switch should not exceed 6 months when patients develop first-line antiretroviral failure in resource-limited settings.

AB - We evaluated adult Nigerian patients with antiretroviral switch to second-line treatment with ritonavir-boosted protease inhibitor (PI/r)-based regimens due to virologic failure (confirmed HIV-1 RNA viral load [VL] >1000 copies/mL) during first-line antiretroviral therapy. Proportion of patients with VL >400 copies/mL and characteristics associated with nonsuppression during second-line treatment are described. Approximately 15% of patients (34 of 225) had VL >400 copies/mL at 1-year after treatment switch to PI/r-based regimens. In adjusted analyses, VL ≥5 log10 copies/mL at treatment switch (odds ratio [OR] 2.90 [confidence interval (CI) 1.21-6.93]); duration of first-line treatment after virologic failure >180 days (OR 2.56 [CI 1.0-6.54]); and PI/r regimen adherence <90% (OR 3.27 [CI 1.39-7.68]) were associated with VL >400 copies/mL at 1 year of second-line treatment. We therefore recommend that the maximum permissible time between suspicion of virologic failure and completion of antiretroviral treatment switch should not exceed 6 months when patients develop first-line antiretroviral failure in resource-limited settings.

KW - ART

KW - antiretroviral

KW - first-line

KW - treatment switch

KW - virologic failure

UR - http://www.scopus.com/inward/record.url?scp=84880428822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880428822&partnerID=8YFLogxK

U2 - 10.1177/1545109712463733

DO - 10.1177/1545109712463733

M3 - Article

C2 - 23128403

AN - SCOPUS:84880428822

VL - 12

SP - 236

EP - 240

JO - Journal of the International Association of Providers of AIDS Care

JF - Journal of the International Association of Providers of AIDS Care

SN - 2325-9574

IS - 4

ER -